Loading...
•
Sep 30, 2024
Generation Bio Q3 2024 Earnings Report
Generation Bio's Q3 2024 financial results were reported, highlighting a decrease in net loss compared to the same quarter last year and a strong cash position expected to fund operations into 2H 2027.
Key Takeaways
Generation Bio reported a net loss of $15.3 million for Q3 2024, an improvement compared to the $28.3 million net loss in Q3 2023. The company's cash, cash equivalents, and marketable securities totaled $199.8 million as of September 30, 2024, which is expected to fund operations into the second half of 2027.
Cash balance of $199.8 million expected to fund operations into 2H 2027.
R&D expenses decreased to $15.1 million compared to $21.9 million in Q3 2023.
G&A expenses decreased to $9.2 million compared to $11.6 million in Q3 2023.
Net loss improved to $15.3 million, or $0.23 per share, compared to $28.3 million, or $0.43 per share, in Q3 2023.
Revenue by Segment
Forward Guidance
Generation Bio expects its cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditures into the second half of 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...